INTRODUCTION {#s1}
============

With growing evidence for the clinical activity of PARP inhibitors in several cancer entities, mutations in genes involved in HR are increasingly recognized as possible biomarkers, although the molecular events responsible for the development of resistance are incompletely understood ([@MCS003657HORC19]). Advanced prostate cancer is often characterized by germline and somatic alterations of genes involved in DNA repair via homologous recombination (HR) ([@MCS003657HORC21]), which have also been associated with sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition in advanced disease. These data also suggest that a substantial proportion of advanced prostate cancer patients may display "BRCAness" and can benefit from PARP inhibition and/or platinum-based chemotherapy ([@MCS003657HORC18]). Data from a phase 2 study of olaparib in metastatic castration-resistant prostate cancer (CRPC) revealed that 88% of patients that had a response to olaparib harbored one or more deleterious alterations in DNA repair genes ([@MCS003657HORC20]). Here we report the first case of a pathogenic germline *PALB2* (partner and localizer of BRCA2) variant that confers sensitivity to PARP inhibition in a patient with prostate cancer.

Clinical Presentation {#s1a}
---------------------

The patient was diagnosed with locally advanced prostate adenocarcinoma at the age of 43. His family history was not suggestive of a hereditary cancer predisposition syndrome. The prostate-specific antigen (PSA) level at diagnosis was 76 ng/mL. Because of massive bladder neck infiltration, the patient underwent initial transurethral resection, followed by 6 mo of neoadjuvant combined hormonal therapy with leuprorelin and bicalutamide (PSA nadir 0.6 ng/mL) and radical retropubic prostatectomy. Even though the patient had a PSA response, postoperative staging and grading exposed a large tumor with nodal metastasis and positive surgical margins (pT4, pN1, cM0, R1) and a Gleason score of 5 + 4 = 9. Within a month after radical surgery, and despite ongoing hormonal therapy, the patient became castration-refractory and was treated with six cycles of docetaxel chemotherapy. Unfortunately, prostate-specific membrane antigen positron emission tomography after completion of chemotherapy demonstrated disseminated bone and lymph node metastases. Because of a PSA response during chemotherapy, four additional cycles of docetaxel were administered. Zoledronic acid was added to the treatment regimen. The patient developed fatigue and his general condition worsened because of progressive disease and accumulating side effects of chemotherapy (fatigue and muscular weakness leading to Eastern Cooperative Oncology Group \[ECOG\] and World Health Organization \[WHO\] Score 3). Following PSA and radiographic progression with hepatic metastases, therapy with abiraterone acetate and prednisolone was initiated, which could not bring about any treatment benefit.

The primary tumor from the radical prostatectomy was analyzed using whole-genome sequencing and made available for clinical interpretation within the NCT-MASTER (Molecularly Aided Stratification for Tumor Eradication Research) program ([@MCS003657HORC12]). We identified a pathogenic, heterozygous germline *PALB2* mutation ([Table 1](#MCS003657HORTB1){ref-type="table"}) with somatic loss of heterozygosity in the tumor as well as a mutational signature suggestive of defective DNA repair via homologous recombination when analyzing the entirety of somatic SNVs ([@MCS003657HORC3]). This prompted a molecularly informed tumor board recommendation by the NCT MASTER molecular tumor board of PARP inhibitor treatment with or without platinum-based chemotherapy as well as genetic counseling. Single-agent treatment with the PARP inhibitor olaparib resulted in substantial improvement of clinical symptoms, and only moderate side effects (e.g., anemia CTCAE Grade 2) were observed. Remarkably, the patient restarted physical activities and his general condition improved (ECOG/WHO Score 1). However, staging after 6 wk revealed disease progression with 24.1% increase of target lesions. In addition, the PSA value increased during treatment with olaparib monotherapy from 15.2 µg/L to 110 µg/L, whereas LDH decreased from 471 U/L to 297 U/L. Because of the considerable clinical improvement, olaparib treatment was continued and cisplatin (30 mg/m^2^ i.v. weekly) was added. Magnetic resonance imaging after 2 mo of olaparib/cisplatin therapy showed disease stabilization by Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria ([Fig. 1](#MCS003657HORF1){ref-type="fig"}). Addition of cisplatin resulted in a mild decrease of PSA to 96.4 µg/L as well as of LDH to 278 U/L. However, worsening anemia (CTCAE Grade 3) required transfusion of red blood cells and we observed decreasing neutrophil counts (CTCAE Grade 2).

![Magnetic resonance imaging of liver metastases (*A*) before and (*B*) after 2 mo of olaparib/cisplatin treatment. Two hepatic lesions were selected and their largest diameters measured in comparison according to RECIST 1.1 criteria as defined by PCGW3. Sum of longest diameters of the two target lesions was 6.22 cm before and 5.40 cm after olaparib/cisplatin treatment (13% decrease).](MCS003657Hor_F1){#MCS003657HORF1}

###### 

Variant table

  Gene       Chromosome  HGVS cDNA                     HGVS protein   Variant type          Predicted effect   dbSNP         Genotype                ClinVar
  --------- ------------ ---------------------------- --------------- --------------------- ------------------ ------------- ----------------------- ---------
  *PALB2*        16      NM_024675.3:c.509_510delGA    p.Arg170Ilefs  Frameshift deletion   Loss of function   rs515726123   Germline heterozygous   132267

Three months thereafter, the lymphatic and hepatic metastases progressed and clinical symptoms worsened. At time of radiological progression PSA had further decreased to 50.9 µg/L, whereas LDH dramatically increased to 1501 U/L. Given the patient\'s young age and his desire to continue treatment, several experimental salvage regimens were administered. However, no durable stabilization of disease could be achieved and the patient died 5 mo later.

Germline and Somatic Genomic Alterations {#s1b}
----------------------------------------

To identify molecular alterations that could inform experimental therapy in this patient, we used whole-genome and transcriptome sequencing data from the prostatectomy specimen that were obtained at diagnosis within the ICGC early-onset prostate cancer project ([@MCS003657HORC29]) as well as whole-exome and transcriptome sequencing data from a liver metastasis that was obtained upon progression on PARP Inhibitor therapy two and a half years later. Single nucleotide variants (SNVs), small insertions and deletions (indels), copy-number variations (CNVs), genomic structural variations, and gene fusions were interpreted with regard to their clinical significance and ranked according to therapeutic relevance.

Analysis of the primary tumor revealed 14 somatic nonsynonymous SNVs and two somatic indels including a known *TP53* missense variant, NM_000546.5:c.451C\>T, p.(Pro151Ser) (rs28934874) in the DNA-binding domain, which has been previously described as a pathogenic mutation in prostate cancer ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003657/-/DC1); [@MCS003657HORC23]).

We detected a germline frameshift deletion in *PALB2*, NM_024675.3:c.509_510del, p.Arg170Ilefs\*14 (rs515726123) ([Table 1](#MCS003657HORTB1){ref-type="table"}), which has already been described as a pathogenic Polish founder mutation associated with a predisposition for breast and ovarian cancer ([@MCS003657HORC8]). This variant demonstrated somatic loss of heterozygosity with a mutational frequency of 70% in the primary tumor tissue. PALB2 is responsible for BRCA2 nuclear localization and DNA damage response ([@MCS003657HORC30]) and serves as a molecular adaptor between BRCA1 and BRCA2 ([@MCS003657HORC25]). Therefore, absence of PALB2 leads to impaired recruitment of BRCA2 and RAD51 to sites of DNA damage, making it a bona fide tumor suppressor. Germline loss-of-function mutations of *PALB2* have been primarily associated with hereditary susceptibility to breast, ovarian, and pancreatic cancer ([@MCS003657HORC14]; [@MCS003657HORC4]; [@MCS003657HORC24]), whereas homozygous loss of function leads to Fanconi anemia ([@MCS003657HORC22]; [@MCS003657HORC31]).

Interestingly, we detected no other genetic hallmarks of prostate cancer, such as a *TMPRSS2-ETS* fusion or PTEN inactivation. We also observed prominent amplification (total copy number of 6) of the *MYC* proto-oncogene on Chromosome 8q24 ([Fig. 2](#MCS003657HORF2){ref-type="fig"}A), a common alteration in prostate cancer associated with increased aggressiveness ([@MCS003657HORC27]; [@MCS003657HORC13]; [@MCS003657HORC11]), which was accompanied by increased *MYC* mRNA expression. Another amplicon on Chromosome 2p24 encompassed the *MYC* family member *MYCN*. However, *MYCN* mRNA expression was not elevated in the primary tumor, in agreement with the observation that MYC and MYCN activation are mutually exclusive events in advanced prostate cancer ([@MCS003657HORC7]) and MYCN expression is often associated with a neuroendocrine phenotype ([@MCS003657HORC6]). Of note, *MYCN* expression was increased 4.8-fold in the therapy-resistant metastasis as compared to the primary tumor. Comparison of the primary and metastatic samples demonstrated no apparent evolution of CNVs contributing to additional oncogenic events, whereas extensive genomic rearrangements were evident at both time points ([Fig. 2](#MCS003657HORF2){ref-type="fig"}A). We also performed a supervised analysis of known mutational signatures ([@MCS003657HORC3]) and observed a strong contribution of signature Alexandrov-COSMIC 3, which is associated with defective HR DNA repair, to the mutational catalog in both the primary tumor and the metastasis ([Fig. 2](#MCS003657HORF2){ref-type="fig"}B).

The liver metastasis harbored 69 somatic nonsynonymous SNVs and two somatic indels ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003657/-/DC1)). The *TP53* mutation as well as five other SNVs and both indels identified in the primary tumor could not be detected in the metastasis, suggesting subclonal selection and evolution of the primary tumor during therapy. However, the distribution of allele frequencies of synonymous and nonsynonymous SNVs in both samples was influenced mainly by the tumor cell content and similar between the two samples ([Fig. 2](#MCS003657HORF2){ref-type="fig"}C). Interestingly, the metastasis carried a novel translocation, resulting in an in-frame fusion of *RB1* exon 3 and exon 2 of *COL28A1*, encoding a collagen subtype, and was predicted to cause loss of retinoblastoma protein function ([Fig. 3](#MCS003657HORF3){ref-type="fig"}). We also observed discrete changes in the transcriptional profile, in particular up-regulation of several genes characteristic for the neuroendocrine prostate cancer phenotype such as *MYCN*, *AURKA*, *EZH2*, and *DNMT1* ([@MCS003657HORC6]).

![(*A*) DNA copy-number profiles of the primary tumor (*upper* panel) and metastasis (*lower* panel). (*B*) Relative contributions of mutational signatures (Alexandrov-COSMIC, AC) in the primary tumor (*upper* panel) and metastasis (*lower* panel) depicting the prevalence of the AC3 signature. (*C*) Distribution of measured allele frequencies of all somatic synonymous and nonsynonymous SNVs in both samples.](MCS003657Hor_F2){#MCS003657HORF2}

![Fusion between exon 3 of *RB1* and exon 2 of *COL28A1*. *Upper* panels show the sequencing coverage and exon structure of the *RB1* and *COL28A1* as well as the structure of the putative fusion transcript. Chromatogram of the Sanger sequencing showing the nucleotide sequence of the fusion region is shown *below*.](MCS003657Hor_F3){#MCS003657HORF3}

DISCUSSION {#s2}
==========

Our observations suggest that deleterious germline *PALB2* variants represent an actionable target in metastatic CRPC and support extended genomic testing in this patient population. CRPC has been reported to be a very heterogeneous entity and several molecular subtypes have recently been defined ([@MCS003657HORC1]). Among these, tumors with DNA repair alterations might be particularly amenable to precision oncology approaches as a plethora of DNA repair genes may be linked to PARP inhibitor sensitivity. Recent studies have established the occurrence of germline *PALB2* mutations in prostate cancer as well as the sensitivity of other *PALB2* deficient tumor entities to PARP inhibition ([@MCS003657HORC10]; [@MCS003657HORC20]). However, not every patient with DNA repair defects may experience clinical benefit, and the identification and detailed characterization of predictive biomarkers is an ongoing effort. A germline missense variant in the *FANCA* gene has been associated with exceptional response to platinum in neuroendocrine prostate cancer ([@MCS003657HORC5]). In our case, we observed an initial response to PARP inhibition combined with platinum-based therapy, which was followed by progression of an aggressive tumor resistant to further treatment and displaying newly acquired somatic genetic alterations typically associated with neuroendocrine prostate cancer, such as an inactivating *RB1* fusion and elevated *MYCN* expression ([@MCS003657HORC26]; [@MCS003657HORC6]). We did not find evidence for restoration of HR proficiency leading to secondary resistance to olaparib. We also hypothesize that resistance to PARP inhibition in prostate adenocarcinoma with "BRCAness" might co-occur with the emergence of neuroendocrine transdifferentiation ([@MCS003657HORC2]).

In summary, this comprehensive genomic and transcriptomic analysis indicates that pathogenic germline mutations in *PALB2* are associated with hallmarks of defective HR, including extensive structural genomic rearrangements and enrichment of specific mutational signatures, and might predict response to PARP inhibition as well as platinum-based chemotherapy. We propose that multidimensional genomic characterization of prostate cancer patients undergoing PARP inhibitor therapy will be necessary to define the entire spectrum of predictive biomarkers.

METHODS {#s3}
=======

Next-Generation Sequencing, Bioinformatic Analysis, and Target Validation {#s3a}
-------------------------------------------------------------------------

Whole-genome, whole-exome, and RNA sequencing were performed as described previously ([@MCS003657HORC29]; [@MCS003657HORC16]). The fusion transcript was validated by Sanger sequencing. SNVs and indels were identified using previously reported bioinformatics pipelines ([@MCS003657HORC29]). Structural variants were called with CREST ([@MCS003657HORC28]). CNVs were extracted from whole-exome sequencing data with CNVkit (version 0.8.3.dev0). For the extraction of CNVs from whole-genome sequencing data we used our in-house CNV calling pipeline ACEseq (version 1.0.189) ([@MCS003657HORC15]). A supervised analysis of mutational signatures to determine the contributions of known mutational signatures to the mutational catalog of individual samples was performed as described previously ([@MCS003657HORC9]). RNA-sequencing reads were mapped to the GRCh37.p13 assembly of the human reference genome using STAR 2.4.1c with the following alignment parameters:--outFilterMultimapNmax 10 --outFilterScoreMinOverLread 0.66 --outFilterMatchNmin 0 --outFilterMatchNminOverLread 0.66 --outFilterMismatchNmax 10 --outFilterMismatchNoverLmax 0.3 --clip5pNbases 0 --clip3pNbases 0 --clip3pAfterAdapterNbases 0 --clip3pAdapterSeq AGATCGGAAGAG --clip3pAdapterMMp 0.1 --seedSearchLmax 0 --seedSearchStartLmax 50 --alignIntronMin 21 --alignIntronMax 0 --alignMatesGapMax 0 --alignEndsType Local --alignSoftClipAtReferenceEnds No --chimSegmentMin 15 --chimScoreMin 1 --chimJunctionOverhangMin 15. The expression of genes annotated in the GencodeV19 gene model was quantified with featureCounts (version 1.4.6-p2) ([@MCS003657HORC17]). High-confidence gene fusion predictions were extracted from chimeric alignments produced by STAR using our in-house pipeline Arriba (version 0.8), which removes recurrent alignment artifacts, transcript variants also observed in normal tissue, and reads with low sequence complexity as well as events with short anchors or breakpoints in close proximity or a low number of supporting reads relative to the overall number of predicted events in a gene. Sequencing coverage metrics are provided in [Supplemental Table S2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003657/-/DC1).

ADDITIONAL INFORMATION {#s4}
======================

Data Deposition and Access {#s4a}
--------------------------

The raw analytical data have been deposited in the European Genome-phenome Archive (<https://www.ebi.ac.uk/ega/datasets>) under accession numbers EGAS00001000383 (primary tumor, patient ID EOPC-125) and EGAS00001003133 (metastasis). Oncological outcome data were collected via the Progether PROM\'s (patient reported outcome measurement) interface ([www.progether.com](www.progether.com)).
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